To the Editor Hall et al1 describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA in the Phase 3 Study of Aducanumab in Early Alzheimer’s Disease (EMERGE and ENGAGE) trials,2 we believe this work is of particular interest as it points out ARIA as a timely research and clinical priority, prompting the urgent need to define standardized guidelines for the treatment and follow-up monitoring of such side events.
Piazza F, Frölich L, Padovani A. Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities. JAMA Neurol. 2022;79(6):633–634. doi:10.1001/jamaneurol.2022.0731
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.